Who is sponsoring NCT06073912?

NCT06073912 is sponsored by Cairo University.

What drugs are being tested in NCT06073912?

Interventions in NCT06073912: Open sinus lifting, Collecting blood sample, Bone graft harvesting, Autogenous corticocancellous block graft, Mineralized plasmatic matrix graft, Centrifuge, ACM bur.

What condition does NCT06073912 study?

NCT06073912 studies Maxillary Sinus Floor Elevation.

Is NCT06073912 still recruiting?

NCT06073912 is currently status unknown. Last updated 10 October 2023.

Last reviewed 2023-10-10 · How we verify

NCT06073912

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Implant Placement With Corticocancellous Bone Block vs Mineralized Plasmatic Matrix in Maxillary Sinus Lifting

Status unknown NA Last updated 10 October 2023

What this trial tests

NA trial testing Open sinus lifting in Maxillary Sinus Floor Elevation in 24 participants. Status unknown.

Timeline

1 December 2023

Primary endpoint
1 April 2024

1 June 2024

Quick facts

Lead sponsor	Cairo University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	24
Start date	1 December 2023
Primary completion	1 April 2024
Estimated completion	1 June 2024

Drugs / interventions tested

Open sinus lifting
Collecting blood sample
Bone graft harvesting
Autogenous corticocancellous block graft
Mineralized plasmatic matrix graft
Centrifuge
ACM bur

Conditions studied

Maxillary Sinus Floor Elevation — all drugs for Maxillary Sinus Floor Elevation →

Sponsor

Cairo University

Who can join

Adults 18 to 70, any sex, with Maxillary Sinus Floor Elevation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Maxillary sinus floor elevation is a predictable and effective procedure for increasing the height of the residual bone in the posterior maxilla. The sinus lift procedure is basically performed using Conventional lateral sinus floor elevation (CLSFE) when RBH \< 5 mm. The use of autogenous corticocancellous bone block allows the simultaneous placement of an implant in the severely atrophic maxilla. Autogenous corticocancellous block will be applied in these patients to decrease the number of surgical interventions and the complications related to the surgery, without any additional risk, as well as to provide graft stabilization with the implant itself, using a mechanism similar to that of a screw and nut. Although the traditional application of sticky bone inside the sinus gives the benefit of moldable shaping and accurate fit into the recipient bony cavity which hardens and allows for implant osteotomy and installation with adequate implant stability. Limited comparative studies of both techniques had been introduced to the literature. This study is aimed to compare the quantity of bone gain after open sinus lift and augmentation using autogenous corticocancellous bone blocks from the chin area versus autogenous particulate mineralized plasmatic matrix (sticky bone) graft used as control group. The primary outcome which is amount of bone gain will be measured and secondary stability of the implant.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Cairo University trials

Trials by the same sponsor.

NCT04155528 — Effect of Music Therapy on Postoperative Health Outcomes · NA · not yet recruiting
NCT07363239 — CBCT-Based Safety Distance for Implant Placement Near the Inferior Alveolar Canal · not yet recruiting
NCT07374575 — Egyptian Dental Professionals' Perspectives on the Oral Microbiome and Exosomes · not yet recruiting
NCT07381153 — In-Vitro Cytotoxicity Assessment of INOX (Nanoksa G Plus) Polymer Discs · not yet recruiting
NCT07375394 — 3D-Printed Extraoral Camera for Standardized Dental Photography · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06073912 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cairo University
Last refreshed: 10 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06073912.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing